Claris Biotherapeutics, Claris Bio, CSB-001, oremepermin alfa, limbal stem cell deficiency, LSCD, ophthalmology, visual acuity, corneal regeneration, AAO 2026, clinical trial,

SAN FRANCISCO, Calif. — October 11, 2026 Claris Biotherapeutics, Inc. announced positive proof-of-concept results for CSB-001 (oremepermin alfa ophthalmic...